US5998639A - Sulfatation of estrogen mixtures - Google Patents
Sulfatation of estrogen mixtures Download PDFInfo
- Publication number
- US5998639A US5998639A US08/852,625 US85262597A US5998639A US 5998639 A US5998639 A US 5998639A US 85262597 A US85262597 A US 85262597A US 5998639 A US5998639 A US 5998639A
- Authority
- US
- United States
- Prior art keywords
- mixture
- equilin
- delta
- compounds
- together represent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Definitions
- the invention relates to a method for the preparation of a mixture of sulfated estrogens, more particularly to the sulfatation of a mixture containing 3-hydroxy-estra-1,3,5(10),8(9)-tetra-en-17-one [delta(8,9)-dehydro estrone; delta(8,9)DHE; delta 8 estrone; 8,9 dehydro estrone; CAS no. 61612-83-7].
- the sodium sulfate of the delta(8,9) derivative of estrone [delta(8,9)DHES] is present in minor amounts of about 3-4% in natural conjugated estrogen compositions, for instance in the commercially available product Premarin® which is being used in hormone replacement therapy.
- estrone sodium sulfate In addition to estrone sodium sulfate, several components have been identified in natural conjugated estrogen compositions among others the sodium sulfates of equilin (in amounts of 22.5-30.5%), 17 alfa dihydro equilin (13.3-19.5%), 17 beta dihydro equilin (0.5-4.0%), 17 alfa estradiol (2.5-9.5%) 17 beta estradiol ( ⁇ 4.5%) and delta(8,9)-dehydro estrone ( ⁇ 12.5%) (U.S. Pharmacopoeia, 1995, p. 627).
- delta(8,9)DHES which has a relatively low affinity to the estrogen receptor, has a high functional activity, which may play a role in the reported LDL-cholesterol-reducing properties and cardiovascular effects of conjugated estrogens, in particular of Premarin®.
- the present invention offers the first easy and inexpensive method of production of sulfated steroid mixtures containing delta(8,9)DHE through sulfatation of an estrogen mixture containing delta(8,9)DHE or derivatives thereof which can be obtained by isomerization of equilin or a derivative thereof.
- mixtures of estrogens comprising a compound according to the general formula I ##STR1## wherein R 1 is H, R 2 is H and R 3 is O-acyl; or
- R 3 is H and R 2 is O-acyl
- R 2 and R 3 together represent O can be sulfated in admixture with one or more compounds taken from the group of compounds of general formula II ##STR2## wherein R 1 , R 2 and R 3 have the previously defined meanings and the dotted line at position 7-8 represents an optional double bond.
- R 2 and R 3 in formula I and/or II represent O. More preferably, delta 8,9 estrone is sulfated in admixture with equilin.
- compounds of general formula II are one or more of the precursors of the minor components as present in natural conjugated estrogen mixtures such as sulfate esters of 17 alfa dihydro equilin, 17 beta dihydro equilin, 17 alfa estradiol and 17 beta estradiol.
- the ratio of the compounds in the reaction mixture is not critical but for economical reasons the preferred ratio is the ratio as present in natural mixtures.
- the compounds of general formula I can be prepared by isomerization of equilin and said derivatives which are indicated in Formula III: ##STR3## wherein R 1 is silyl(alkyl) 3 or O-tetrahydropyranyl, R 2 and R 3 together represent O; or R 2 and R 3 together represent acetal or cyclic acetal.
- alkyl as used in the definition of the formulas, means a branched or unbranched alkyl group having preferably 1-7 carbon atoms, like hexyl, isobutyl, tertiary butyl, propyl, isopropyl, ethyl, and methyl.
- silyl(alkyl) 3 is Si(Me) 2 tert.butyl.
- acyl means an acyl group derived from an alkylcarboxylic acid, the alkyl moiety having the meaning given previously, or derived from formic acid. Acetals are derived from alcohols having preferably 1-6 carbon atoms.
- tetrahydropyranyl also equivalent mixed acetals or mixed hemithioacetals are meant such as e.g. ethoxyethyl, methoxyethyl(MOM), methylmethoxyethyl, methoxyethoxymethyl (MEM), tetrahydrofuranyl, methylthiomethyl, tetrahydrothiopyranyl, tetrahydrothiofuranyl or ethers as methyl and tert-butyl as described in Protective Groups in Organic Synthesis, by Greene, Th. and Wuts, P. (1991), chapter 2, p.14-87.
- the isomerization can be performed using lithium salts of ethylenediamine. This method results into the production of very pure delta(8,9)DHE.
- lithium salts can be prepared by treatment of ethylenediamine with lithium or with alkyllithium, preferably with methyllithium.
- (Co)solvents like tetrahydrofuran, dimethylsulfoxide, and the like may be added. Usually mixtures of derivatives of delta(8,9)DHE and equilin are obtained when (co)-solvents are added.
- Lithium amide in dimethylsulfoxide also provides mixtures of delta(8,9)DHE and equilin or derivatives thereof, which can be converted according to the present invention into their sodium sulfates, to be used in the manufacture of pharmaceutical compositions containing conjugated estrogens.
- the C3 position is occupied by a tetrahydropyranyl ether because such an ether can easily be prepared on an aromatic group, is stable under the isomerization conditions, and, after isomerization, can easily be removed to prepare a hydroxyl group for sulfatation.
- R 1 in formula III is silyl(alkyl) 3
- the isomerization is preferably performed at a temperature of between about 0 and 90° C., and with more preference at about 30° C. if equilin or a derivative thereof is treated with a lithium salt of ethylenediamine or about 65° C. if equilin or a derivative thereof is treated with lithium amide in dimethylsulfoxide.
- R 1 is tetrahydropyranyl a mixture of the substrate and an aforementioned solvent is treated with a lithium salt of ethylenediamine at a temperature of between about -78° C. and 50° C., preferably between approximately 0° C. and -20° C. using THF as the cosolvent.
- R 1 is silyl(alkyl) 3 or tetrahydropyranyl
- the derivatives can be isomerized and subsequently hydrolyzed resulting in compounds according to formula I or a mixture of compounds according to formulas I and III wherein R 1 is H by treatment with mild acid such as dilute ( ⁇ 0.2 N) hydrochloric acid, 50% acetic acid with cosolvents like THF, acetone, methylene chloride, ethanol or by treatment of the derivatives under neutral conditions like trimethylsilyl iodide/trimethylsilyl bromide in methylene chloride; methyl iodide in acetone, H 2 O, NaHCO 3 ; pyridinium p-toluenesulfonate, tert-butanol; tetrabutylammonium fluoride in methylene chloride; AgNO 3 in acetone as described in Protective Groups in Organic Synthesis, by Greene, Th. and Wut
- the thus obtained estrogen derivative mixture can be sulfated according to the invention in admixture with one or more mono acyl derivatives of the group of 17 alfa dihydro equilin, 17 beta dihydro equilin, 17 alfa estradiol and 17 beta estradiol.
- Lithium (13 g) was added portionwise to 920 ml of ethylenediamine under an atmosphere of nitrogen at 95° C. and the mixture was stirred for 30 min. at 100° C.
- the reaction mixture was cooled to 23° C., after which 100 g of equilin were added at a temperature of ⁇ 30° C.
- the mixture was stirred for another 2 h at 30° C.
- the suspension was poured into 2.5 l of ice water and at a temperature ⁇ 25° C. acetic acid was added until pH 7.
- the aqueous layer was extracted three times with 2.5 l of ethyl acetate.
- the organic layer was washed with water, 5 g of active carbon (Norit®) were added and the suspension was stirred at 21° C.
- delta(8,9)DHE and equilin were determined using 1 H-NMR spectroscopy, characteristic peaks of which are 0.90 ppm (C18) for delta(8,9)DHE and 5.53 ppm (C7) and 0.79 ppm (C18) for equilin.
- Lithium amide (5 g) was added to a mixture of 5 g of equilin in 150 ml of DMSO. The mixture was heated to 65° C. and stirred for 70 min. The reaction mixture was poured into 500 ml of water and acidified to pH 6.5 using 4N hydrochloric acid. The crystals were filtered off, washed with water and dried under vacuum at 40° C. to obtain 5 g of a 4:5 mixture of equilin and delta(8,9)-dehydro estrone.
- the suspension was poured into ice water and the mixture was extracted with ethyl acetate. After evaporation of the ethyl acetate extract until a volume of 20 ml was reached and cooling to 0° C., 2 g of crystalline delta 8-estrone was isolated.
- Lithium (1,1 g) was added portionwise to 80 ml of ethylenediamine under an atmosphere of nitrogen at 100° C. and the mixture was stirred for 30 min. at 100° C.
- the reaction mixture was cooled to 23° C., after which 4 g of 17 ⁇ -dihydroequilin were added at a temperature of ⁇ 30° C.
- the mixture was stirred for another 4 h at 30° C.
- the suspension was poured into 250 ml of ice water and at a temperature of ⁇ 25° C. acetic acid was added until pH 7.
- the suspension was cooled to 5° C. and the crystals were filtered off.
- the crystals were suspended in 150 ml of water and 100 ml of ethyl acetate were added.
- the suspension was stirred for 1 h at 15° C., after which the crystals were filtered off, washed with water and dried under vacuum at 45° C., to obtain 2.0 g of 8,9-dehydro-estrone-3-methylether, having a purity of approx. 80%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/852,625 US5998639A (en) | 1995-11-06 | 1997-05-07 | Sulfatation of estrogen mixtures |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95202990 | 1995-11-06 | ||
| US08/744,513 US5739363A (en) | 1995-11-06 | 1996-11-06 | Isomerisation of equilin |
| US08/852,625 US5998639A (en) | 1995-11-06 | 1997-05-07 | Sulfatation of estrogen mixtures |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/744,513 Continuation-In-Part US5739363A (en) | 1995-11-06 | 1996-11-06 | Isomerisation of equilin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5998639A true US5998639A (en) | 1999-12-07 |
Family
ID=27806546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/852,625 Expired - Fee Related US5998639A (en) | 1995-11-06 | 1997-05-07 | Sulfatation of estrogen mixtures |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US5998639A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030207855A1 (en) * | 2000-03-10 | 2003-11-06 | Hill Edward N. | Novel estrogenic compounds |
| WO2003057855A3 (en) * | 2002-01-08 | 2003-12-31 | Endeavor Pharmaceuticals | Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex |
| US20040198670A1 (en) * | 2003-04-04 | 2004-10-07 | Hill Edward N. | Novel estrogenic compounds |
| US20040209853A1 (en) * | 1999-04-06 | 2004-10-21 | Louw Van Der Jaap | Orally active 7.alpha.-alkyl androgens |
| US20040259851A1 (en) * | 2003-04-11 | 2004-12-23 | Leonard Thomas W. | Methods of administering estrogens and progestins |
| US20070142307A1 (en) * | 2000-03-10 | 2007-06-21 | Barr Laboratories, Inc. | Novel estrogenic compounds |
| CN100333708C (en) * | 2005-07-20 | 2007-08-29 | 武汉大学 | Cyclic aldehyde acetal used as initiator aid of dental filling visible light curing filling compounding material |
| US20090012319A1 (en) * | 2004-08-04 | 2009-01-08 | N.V. Organon | Process for the preparation 2-substituted-derivatives of estrone and estradiol |
| US20100234330A1 (en) * | 2003-07-23 | 2010-09-16 | Hill Edward N | Novel Estrogenic Compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB697531A (en) * | 1951-04-17 | 1953-09-23 | S B Penick & Company | Improvements in or relating to the preparation of estrane sulfate salts |
| US5210081A (en) * | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
| US5395831A (en) * | 1994-04-08 | 1995-03-07 | American Home Products Corporation | Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone |
| EP0771816A2 (en) * | 1995-11-06 | 1997-05-07 | Akzo Nobel N.V. | Isomerisation of equilin |
-
1997
- 1997-05-07 US US08/852,625 patent/US5998639A/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB697531A (en) * | 1951-04-17 | 1953-09-23 | S B Penick & Company | Improvements in or relating to the preparation of estrane sulfate salts |
| US5210081A (en) * | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
| US5395831A (en) * | 1994-04-08 | 1995-03-07 | American Home Products Corporation | Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone |
| EP0771816A2 (en) * | 1995-11-06 | 1997-05-07 | Akzo Nobel N.V. | Isomerisation of equilin |
| US5739363A (en) * | 1995-11-06 | 1998-04-14 | Akzo Nobel, N. V. | Isomerisation of equilin |
Non-Patent Citations (10)
| Title |
|---|
| "FDA Panel--No Decision on Oestrogens", SCRIP, 2049:15, 1995. |
| Ayanoglu et al., Tetrahedron, 35:13:1591 1594, 1979. * |
| Ayanoglu et al., Tetrahedron, 35:13:1591-1594, 1979. |
| FDA Panel No Decision on Oestrogens , SCRIP, 2049:15, 1995. * |
| Jenkins et al. The Preparation and Properties of Steriod Sulfate Esters, Methods in Enzymology, 15, 351 358, 1969. * |
| Jenkins et al. The Preparation and Properties of Steriod Sulfate Esters, Methods in Enzymology, 15, 351-358, 1969. |
| K.M. Mcerlane et al., Journal of Pharmaceutical Sciences, 66:4:523 526, 1977. * |
| K.M. Mcerlane et al., Journal of Pharmaceutical Sciences, 66:4:523-526, 1977. |
| R.W. Roos, Journal of Chromatographic Science, 14:11:505 512, 1976. * |
| R.W. Roos, Journal of Chromatographic Science, 14:11:505-512, 1976. |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040209853A1 (en) * | 1999-04-06 | 2004-10-21 | Louw Van Der Jaap | Orally active 7.alpha.-alkyl androgens |
| US7179799B2 (en) | 2000-03-10 | 2007-02-20 | Barr Laboratories, Inc. | (3) and (6) substituted estrogenic compounds |
| US6660726B2 (en) | 2000-03-10 | 2003-12-09 | Endeavor Pharmaceuticals | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
| US7459445B2 (en) | 2000-03-10 | 2008-12-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and topical pharmaceutical formulations of the same |
| US7749989B2 (en) | 2000-03-10 | 2010-07-06 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds, methods of using and methods of administering the same |
| US20030207855A1 (en) * | 2000-03-10 | 2003-11-06 | Hill Edward N. | Novel estrogenic compounds |
| US6844334B2 (en) | 2000-03-10 | 2005-01-18 | Endeavor Pharmaceuticals | (3) and (6) substitued estrogenic compounds |
| US20070142307A1 (en) * | 2000-03-10 | 2007-06-21 | Barr Laboratories, Inc. | Novel estrogenic compounds |
| US20090105198A1 (en) * | 2000-03-10 | 2009-04-23 | Duramed Pharmaceuticals, Inc. | Novel estrogenic compounds |
| US20060041151A1 (en) * | 2002-01-08 | 2006-02-23 | Barr Laboratories, Inc. | Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex |
| US20070225512A1 (en) * | 2002-01-08 | 2007-09-27 | Leonard Thomas W | Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex |
| AU2003206404B2 (en) * | 2002-01-08 | 2008-05-29 | Barr Laboratories, Inc. | Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex |
| WO2003057855A3 (en) * | 2002-01-08 | 2003-12-31 | Endeavor Pharmaceuticals | Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex |
| EP1463748A4 (en) * | 2002-01-08 | 2009-10-21 | Barr Lab Inc | Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex |
| US6992075B2 (en) | 2003-04-04 | 2006-01-31 | Barr Laboratories, Inc. | C(14) estrogenic compounds |
| US20040198670A1 (en) * | 2003-04-04 | 2004-10-07 | Hill Edward N. | Novel estrogenic compounds |
| US20040259851A1 (en) * | 2003-04-11 | 2004-12-23 | Leonard Thomas W. | Methods of administering estrogens and progestins |
| US20100234330A1 (en) * | 2003-07-23 | 2010-09-16 | Hill Edward N | Novel Estrogenic Compounds |
| US7989436B2 (en) | 2003-07-23 | 2011-08-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and pharmaceutical formulations comprising the same |
| US20090012319A1 (en) * | 2004-08-04 | 2009-01-08 | N.V. Organon | Process for the preparation 2-substituted-derivatives of estrone and estradiol |
| US7910756B2 (en) | 2004-08-04 | 2011-03-22 | N.V. Organon | Process for the preparation 2-substituted-derivatives of estrone and estradiol |
| US20110152544A1 (en) * | 2004-08-04 | 2011-06-23 | N. V. Organon | Process for the preparation 2-substituted derivatives of estrone and estradiol |
| CN100333708C (en) * | 2005-07-20 | 2007-08-29 | 武汉大学 | Cyclic aldehyde acetal used as initiator aid of dental filling visible light curing filling compounding material |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5998639A (en) | Sulfatation of estrogen mixtures | |
| JPS5931800A (en) | 19-thio-androstane derivative | |
| EP0056000B1 (en) | 17-(alkoxycarbonyl)(formamide)methylene steroid derivatives and their preparation | |
| FR2569408A1 (en) | NOVEL STEROIDS SUBSTITUTED IN POSITION 10 BY A RADICAL COMPRISING A DOUBLE OR TRIPLE BINDING, THEIR PROCESS OF PREPARATION, THEIR APPLICATION AS MEDICAMENTS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| EP0875515B1 (en) | Sulfatation of estrogen mixtures | |
| HU176715B (en) | Process for preparing 17alpna-ethinyl-3,7,17beta-trihadroxy-estratriene derivatives | |
| US3072686A (en) | 16alpha-alkyl-pregnane compounds and process for their manufacture | |
| RU2009146C1 (en) | Method for producing derivatives of 19-norprogesterone | |
| DE1793618C3 (en) | 03/07/63 USA 263441 Process for the production of 3-hydroxy-1,5-bisdehydrosteroids of the androstane series | |
| EP0430386B1 (en) | 14Alpha, 17alpha bridged 16-hydroxyestratrienes | |
| US5321019A (en) | Bile acid sulfurated derivatives | |
| MXPA98003465A (en) | Sulfatation of estrog mixes | |
| DE2037402A1 (en) | Process for the production of 7 alpha methyl steroid derivatives | |
| US4022892A (en) | 17β-Ethynyl-3,17α-estradiol and derivatives thereof | |
| US3096350A (en) | 6, 16alpha-dimethyl-delta1, 4, 6-pregnatriene-17alpha-ol-3, 20-dione and esters thereof | |
| US3960842A (en) | Process for the preparation of 17β-oxalyl steroids | |
| US3631077A (en) | New 16alpha-alkyl-steroids | |
| CZ290448B6 (en) | Equilin isomerization process | |
| US3275665A (en) | Process for the preparation of delta9(11)-steroid compounds | |
| US2686780A (en) | Hydrolysis of 3, 20-diacyloxy-9 (11), 17 (20)-dioxido-5, 7-pregnadiene adducts | |
| JP2640239B2 (en) | Protostar-13 (17) ene-3,16-dione compound | |
| US3136790A (en) | Process of preparation of steroids having a double bond in the 5, 10-position | |
| US4097477A (en) | Steroid compounds and processes thereof | |
| MC1121A1 (en) | NEW D-HOMOSTEROIDS | |
| US3076824A (en) | 21-fluoroacetylallo-pregnane-3beta-ol-20-one and derivatives thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: AKZO NOBEL N.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAIJMAKERS, PETRUS H.;HOFSTRAAT, ROBERT G.;VAN DEN BOOM, HENRICUS P.A.J.M.;REEL/FRAME:008637/0324 Effective date: 19970502 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| CC | Certificate of correction | ||
| AS | Assignment |
Owner name: N.V. ORGANON,NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AKZO NOBEL N.V.;REEL/FRAME:018816/0737 Effective date: 20070112 Owner name: N.V. ORGANON, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AKZO NOBEL N.V.;REEL/FRAME:018816/0737 Effective date: 20070112 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20111207 |